Digital Sponsored 12 Questions with Sam Dixey Find out more about Sam Dixey, Head of Medical Affairs Innovation and Technology (MAIT) at LUCENT Biopharma.
R&D Sponsored 12 Questions with Matthew Goodman LUCENT Biopharma's Medical Director Matthew Goodman, a doctor by training, specialises in late-phase Clinical Development and Medical Affairs.
R&D Sponsored 12 Questions with Lucy Walker Lucy Walker is the Head of Medical Operations at the growing medical consultancy LUCENT Biopharma. Find out more in a new 12 Questions With.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.